African trade ministers meet in Cairo to push forward with AfCFTA    Scatec's $3.6bn renewables portfolio part of Egypt's NWFE energy pillar    Egypt's stocks end lower on Sept 16    Egypt launches international architecture academy with UNESCO, European partners    Egypt's President, Pakistan's PM condemn Israeli attack on Qatar    Egypt's PM, Russian deputy PM discuss industrial zone, Dabaa nuclear plant    Egypt signs MoUs with 3 European universities to advance architecture, urban studies    Sisi tells global leaders at Macron's video conference: Israel crossed all red lines    Egypt to begin second phase of universal health insurance in Minya    Madrid trade talks focus on TikTok as US and China seek agreement    Power of Proximity: How Egyptian University Students Fall in Love with Their Schools Via Social Media Influencers    Egypt wins Aga Khan Award for Architecture for Esna revival project    Egypt's Foreign Minister, Pakistani counterpart meet in Doha    Egypt condemns terrorist attack in northwest Pakistan    Egypt advances plans to upgrade historic Cairo with Azbakeya, Ataba projects    Egyptian pound ends week lower against US dollar – CBE    Egypt hosts G20 meeting for 1st time outside member states    Lebanese Prime Minister visits Egypt's Grand Egyptian Museum    Egypt to tighten waste rules, cut rice straw fees to curb pollution    Egypt seeks Indian expertise to boost pharmaceutical industry    Egypt prepares unified stance ahead of COP30 in Brazil    Egypt harvests 315,000 cubic metres of rainwater in Sinai as part of flash flood protection measures    Al-Sisi says any party thinking Egypt will neglect water rights is 'completely mistaken'    Egyptian, Ugandan Presidents open business forum to boost trade    Egypt's Sisi, Uganda's Museveni discuss boosting ties    Egypt's Sisi warns against unilateral Nile measures, reaffirms Egypt's water security stance    Greco-Roman rock-cut tombs unearthed in Egypt's Aswan    Egypt reveals heritage e-training portal    Sisi launches new support initiative for families of war, terrorism victims    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Health ministry pulls 14 diabetes drugs off market over heart complications concerns
Heba Fahmy Published in Daily News Egypt on 26 - 09 - 2010

CAIRO: The Ministry of Health decided to take 14 anti-diabetic drugs off the market to prevent possible health risks.
The ministry stipulated in a statement issued on Saturday, that all drugs that contain rosiglitazone will be pulled from pharmacies throughout Egypt following a statement by the European Medicines Agency (EMA) that the drugs' side effects outweigh their benefits.
On Thursday, the EMA recommended that drugs containing rosiglitazone be suspended from the European pharmaceutical market due to concern over the finding that it raises the risk of heart disease.
Rosiglitazone works as an insulin sensitizer, which is widely used to treat insulin resistance in sufferers of type 2 diabetes. It is sold as a stand-alone drug under the label Avandia, and as an active ingredient in a host of other varieties of drug combinations sold at pharmacies. It is predominately marketed by the pharmaceutical company GlaxoSmithKline (GSK).
Over 13,000 lawsuits have been filed worldwide against GSK because of the drug's side effects, and GSK has agreed to pay settlements in about 10,000 of these legal cases, Bloomberg reported last July.
According to a press release by the EMA, rosiglitazone has been recognized to be associated with fluid retention and an increased risk of heart failure. As a result, the cardiovascular safety of taking the drug must remain under close medical review.
“The drug isn't good and it had many restrictions on it from the start,” Dr. Mahmoud Abdel Maksoud, Secretary General of the Pharmacists Syndicate, told Daily News Egypt. “Whenever a patient used to ask me for it, I would advise him to ask his doctor for an alternative.”
When Avandia was first sold in the pharmaceutical marketplace in 2000, its use was restricted to patients who couldn't tolerate safer alternatives. And even then, most doctors would routinely deter patients with a history of heart failure from taking the drug, according to EMA.
According to the ministry, patients who are currently taking these drugs should discuss suitable alternative treatments with their doctor.
Rosiglitazone is quite controversial in the US. Some experts believe that is has grave health risks and have recommended it be taken off the market, but the US Food and Drug Administration disagreed with the recommendations and has decided to keep it available for purchase under considerable restrictions.

Clic here to read the story from its source.